Skip to main content

Advertisement

Table 4 HbA1c levels as a function of concomitant diabetes drug use and baseline HbA1c levels

From: Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

Medication classification HbA1c classification n Baseline mean ± SD After administration mean ± SD Difference
All patients Total 2086 8.46 ± 1.40 7.71 ± 1.31 -0.76 ± 1.38 §  
  7-8% 1010 7.46 ± 0.29 7.20 ± 0.77 -0.25 ± 0.74 § p < 0.001
  8-9% 555 8.44 ± 0.28 7.75 ± 1.02 -0.69 ± 1.01 §  
  ≥9% 521 10.45 ± 1.29 8.64 ± 1.79 -1.81 ± 1.97 §  
Diabetes drug use Subtotal 254 7.84 ± 1.04 7.28 ± 1.00 -0.56 ± 1.06 §  
Before study: not taken
&
7-8% 186 7.38 ± 0.26 7.06 ± 0.67 -0.32 ± 0.66 p < 0.001
During study: not taken 8-9% 46 8.38 ± 0.26 7.64 ± 1.08 -0.74 ± 1,03 §  
  ≥9% 22 10.64 ± 1.24 8.48 ± 1.85 -2.16 ± 2.03 §  
  Subtotal 397 8.89 ± 1.66 7.42 ± 1.36 -1.47 ± 1.88 §  
Before study: not taken
&
7-8% 147 7.46 ± 0.29 7.06 ± 0.85 -0.39 ± 0.86 § p < 0.001
During study: taken 8-9% 109 8.45 ± 0.29 7.31 ± 0.96 -1.15 ± 0.97 §  
  ≥9% 141 10.73 ± 1.40 7.89 ± 1.84 -2.84 ± 2.30 §  
  Subtotal 59 8.26 ± 1.33 7.79 ± 1.23 -0.47 ± 1.10 ‡  
Before study: taken
&
7-8% 34 7.48 ± 0.28 7.26 ± 0.83 -0.22 ± 0.85 p = 0.003
During study: not taken 8-9% 14 8.50 ± 0.28 8.09 ± 1.03 -0.41 ± 0.93  
  ≥9% 11 10.38 ± 1.67 9.05 ± 1.51 -1.32 ± 1.59 †  
  Subtotal 1376 8.46 ± 1.33 7.86 ± 1.31 -0.60 ± 1.20 §  
Before study: taken
&
7-8% 643 7.48 ± 0.29 7.28 ± 0.76 -0.20 ± 0.73 § p < 0.001
During study: taken 8-9% 386 8.44 ± 0.27 7.88 ± 1.00 -0.56 ± 0.98 §  
  ≥9% 347 10.32 ± 1.22 8.94 ± 1.69 -1.38 ± 1.66 §  
  1. Baseline HbA1c levels for 2086 patients were ≥ 7.0%. A paired t-test was used to assess statistically significant differences from baseline for each group. P values were determined by ANOVA to assess statistically differences from baseline among baseline HbA1c-subgroup